Impact of Cachexia on Chemotherapy Efficacy and Survival in Pancreatic Cancer: A Systematic Review and Meta-Analysis

被引:0
作者
Khalil, Muhammad Ashraf [1 ]
Jafri, Syed Ahsan Ali [2 ]
Naqvi, Midhat E. Zahra [2 ]
Jauhar, Iman [2 ]
Kumar, Vijay [2 ]
Ali, Syed Muhammad Sinaan [2 ]
Khalil, Sara [2 ]
Raheem, Abdul [3 ]
Kumar, Ritesh [2 ]
Haseeb, Abdul [1 ]
Shafique, Muhammad Ashir [1 ]
机构
[1] Jinnah Sindh Med Univ, Dept Med, Iqbal Shaheed Rd, Karachi 75510, Pakistan
[2] Liaquat Natl Hosp & Med Coll, Dept Med, Karachi, Pakistan
[3] Baqai Med Univ, Dept Med, Karachi, Pakistan
关键词
pancreatic cancer; cachexia; chemotherapy; overall survival; treatment failure; meta-analysis; prognosis; observational studies; mortality; East Asian populations; DISTRESS;
D O I
10.1177/10732748241292784
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and ObjectivePancreatic cancer (PC) is a significant cause of cancer-related mortality, with limited curative options and high rates of cachexia, a debilitating syndrome associated with poor prognosis. While previous research has linked sarcopenia to poor outcomes in PC, the correlation between cachexia and treatment outcomes remains underexplored. This meta-analysis aims to investigate the association between cachexia and overall survival and time to treatment failure in advanced PC patients undergoing first-line chemotherapy.MethodA systematic search of electronic databases was conducted following PRISMA guidelines. Eligible studies compared cachexic and non-cachexic PC patients, reporting outcomes of observed survival or time to treatment failure. Data extraction and analysis were performed using Comprehensive Meta-Analysis Version 3.3, employing random-effects models and sensitivity analyses to assess heterogeneity and bias.ResultsSeven observational studies involving 2834 PC patients were included. The incidence of cachexia was 45% (95% CI: 0.27-0.65), with a higher prevalence in East Asian populations. Cachexic patients experienced significantly earlier treatment failure (SDM: -2.22, 95% CI: -2.6 to -1.7, P = 0.0001) and higher mortality risk (HR: 2.02, 95% CI: 1.17-3.48, P = 0.011) compared to non-cachexic patients. Overall survival was lower in cachexic patients (SDM: -2.34, 95% CI: -3.7 to -0.90, P = 0.001), with considerable heterogeneity across studies. Meta-regression analysis revealed significant differences between countries but insignificant correlations with age.ConclusionCachexia is associated with reduced overall survival, early chemotherapy failure, and elevated mortality in advanced PC patients undergoing first-line chemotherapy. Recognition and management of cachexia are crucial for optimizing treatment outcomes and improving patient survival. Future research should focus on prospective studies to better understand the impact of cachexia on treatment response and develop tailored interventions to mitigate its adverse effects. Pancreatic cancer (PC) presents a formidable challenge due to its limited treatment options and association with cachexia, a debilitating condition linked to poor prognosis. This meta-analysis investigates the relationship between cachexia and treatment outcomes in advanced PC patients undergoing first-line chemotherapy. Seven observational studies encompassing 2834 patients were analyzed, revealing a 45% incidence of cachexia, notably higher in East Asian populations. Cachexic patients exhibited earlier treatment failure and higher mortality risk compared to non-cachexic counterparts. Their overall survival was significantly reduced, although with notable heterogeneity across studies. Meta-regression analysis highlighted variations between countries but found no significant correlation with age. The findings underscore the importance of recognizing and addressing cachexia to optimize treatment outcomes and enhance patient survival. Future research should emphasize prospective studies to further elucidate cachexia's impact on treatment response and develop tailored interventions to alleviate its adverse effects.
引用
收藏
页数:12
相关论文
共 40 条
  • [1] Cancer-associated cachexia - understanding the tumour macroenvironment and microenvironment to improve management
    Argiles, Josep M.
    Lopez-Soriano, Francisco J.
    Stemmler, Britta
    Busquets, Silvia
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2023, 20 (04) : 250 - 264
  • [2] The Spectrum of Malnutrition/Cachexia/Sarcopenia in Oncology According to Different Cancer Types and Settings: A Narrative Review
    Bossi, Paolo
    Delrio, Paolo
    Mascheroni, Annalisa
    Zanetti, Michela
    [J]. NUTRIENTS, 2021, 13 (06)
  • [3] Brebach R, 2016, PSYCHO-ONCOLOGY, V25, P882, DOI 10.1002/pon.4099
  • [4] MOOSE Reporting Guidelines for Meta-analyses of Observational Studies
    Brooke, Benjamin S.
    Schwartz, Todd A.
    Pawlik, Timothy M.
    [J]. JAMA SURGERY, 2021, 156 (08) : 787 - 788
  • [5] Impact on prognosis of early weight loss during palliative chemotherapy in patients diagnosed with advanced pancreatic cancer
    Carnie, Lindsay
    Abraham, Marc
    McNamara, Mairead G.
    Hubner, Richard A.
    Valle, Juan W.
    Lamarca, Angela
    [J]. PANCREATOLOGY, 2020, 20 (08) : 1682 - 1688
  • [6] FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
    Conroy, Thierry
    Desseigne, Francoise
    Ychou, Marc
    Bouche, Olivier
    Guimbaud, Rosine
    Becouarn, Yves
    Adenis, Antoine
    Raoul, Jean-Luc
    Gourgou-Bourgade, Sophie
    de la Fouchardiere, Christelle
    Bennouna, Jaafar
    Bachet, Jean-Baptiste
    Khemissa-Akouz, Faiza
    Pere-Verge, Denis
    Delbaldo, Catherine
    Assenat, Eric
    Chauffert, Bruno
    Michel, Pierre
    Montoto-Grillot, Christine
    Ducreux, Michel
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) : 1817 - 1825
  • [7] Appraising the Quality of Medical Education Research Methods: The Medical Education Research Study Quality Instrument and the Newcastle-Ottawa Scale-Education
    Cook, David A.
    Reed, Darcy A.
    [J]. ACADEMIC MEDICINE, 2015, 90 (08) : 1067 - 1076
  • [8] FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic Review
    Eshmuminov, Dilmurodjon
    Aminjonov, Botirjon
    Palm, Russell F.
    Malleo, Giuseppe
    Schmocker, Ryan K.
    Abdallah, Raef
    Yoo, Changhoon
    Shaib, Walid L.
    Schneider, Marcel Andre
    Rangelova, Elena
    Choi, Yoo Jin
    Kim, Hongbeom
    Rose, J. Bart
    Patel, Sameer
    Wilson, Gregory C.
    Maloney, Sarah
    Timmermann, Lea
    Sahora, Klaus
    Rossler, Fabian
    Lopez-Lopez, Victor
    Boyer, Emanuel
    Maggino, Laura
    Malinka, Thomas
    Park, Jeong Youp
    Katz, Matthew H. G.
    Prakash, Laura
    Ahmad, Syed A.
    Helton, Scott
    Jang, Jin-Young
    Hoffe, Sarah E.
    Salvia, Roberto
    Taieb, Julien
    He, Jin
    Clavien, Pierre-Alain
    Held, Ulrike
    Lehmann, Kuno
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (07) : 4417 - 4428
  • [9] Definition and classification of cancer cachexia: an international consensus
    Fearon, Kenneth
    Strasser, Florian
    Anker, Stefan D.
    Bosaeus, Ingvar
    Bruera, Eduardo
    Fainsinger, Robin L.
    Jatoi, Aminah
    Loprinzi, Charles
    MacDonald, Neil
    Mantovani, Giovanni
    Davis, Mellar
    Muscaritoli, Maurizio
    Ottery, Faith
    Radbruch, Lukas
    Ravasco, Paula
    Walsh, Declan
    Wilcock, Andrew
    Kaasa, Stein
    Baracos, Vickie E.
    [J]. LANCET ONCOLOGY, 2011, 12 (05) : 489 - 495
  • [10] Effect of cancer cachexia on first-line chemotherapy in patients with advanced pancreatic cancer: a claims database study in Japan
    Furuse, Junji
    Osugi, Fumihiko
    Machii, Koji
    Niibe, Koji
    Endo, Toshimitsu
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (04) : 456 - 463